XTalks

FEBRUARY 5, 2024

Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). The total global revenue from Darzalex was $7.98

Sales 98

Sales Manufacturing FDA Approval Life Science 98